rasagilin krka (rasagílíni krka) tafla 1 mg
krka, d.d., novo mesto - rasagilinum tartrat - tafla - 1 mg
pramipexole alvogen (vasiprex) tafla 0,18 mg
alvogen ehf. - pramipexolum díhýdróklóríð - tafla - 0,18 mg
pramipexole alvogen (vasiprex) tafla 0,088 mg
alvogen ehf. - pramipexolum díhýdróklóríð - tafla - 0,088 mg
requip depot forðatafla 2 mg
glaxosmithkline pharma a/s - ropinirolum hýdróklóríð - forðatafla - 2 mg
requip depot forðatafla 4 mg
glaxosmithkline pharma a/s - ropinirolum hýdróklóríð - forðatafla - 4 mg
requip depot forðatafla 8 mg
glaxosmithkline pharma a/s - ropinirolum hýdróklóríð - forðatafla - 8 mg
ropinirole alvogen (ropinirole portfarma) forðatafla 2 mg
alvogen ehf. - ropinirolum hýdróklóríð - forðatafla - 2 mg
ropinirole alvogen (ropinirole portfarma) forðatafla 4 mg
alvogen ehf. - ropinirolum hýdróklóríð - forðatafla - 4 mg
ropinirole alvogen (ropinirole portfarma) forðatafla 8 mg
alvogen ehf. - ropinirolum hýdróklóríð - forðatafla - 8 mg
sapropterin dipharma
dipharma arzneimittel gmbh - sapropterin díhýdróklóríð - phenylketonurias - Önnur meltingarvegi og efnaskipti vörur, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.